



LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)				ATTY DOCKET NO.: H76.2N-11128-US01		APPLICATION NO.: 10/715912	
				APPLICANT: Martin C. Hinz			
				FILING DATE: November 18, 2003		GROUP: 1616	
REFERENCE DESIGNATION				U.S. PATENT AND PUBLISHED APPLICATION DOCUMENTS			
EXAM'S INIT.		DOCUMENT NUMBER	DATE	NAME	CLASS/ SUBCLASS	FILING DATE IF APPROPRIATE	
J	AA	3097947	7/16/63	Kemmerer	424/617		
J	AB	5480657	1/02/96	Allen	424/617		
J	AC	5795895	8/18/98	Anchors	514/253		
J	AD	6207699	3/27/01		514/419		
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY			
J	BA	410067663-A	3/ 1998	Japan			
J	BB						
OTHER ART (Including Author, Title, Date, Pertinent Pages, Ect.)							
J	CA	Budavari et al.; <i>The Merck Index</i> ; Merck & Co., Inc.; 1989, 11 th Edition, page 2321, and 4116.					
J	CB	Donald Heath; <i>Pulmonary Vascular Disease</i> ; <u>Medical Clinics of North America</u> , Volume 61/Number 6, November 6, 1997, Symposium on Pulmonary disease, pp 1279-1307.					
J	CC	Jules Hirsch; <i>The Treatment of Obesity with Drugs</i> ; <u>The American journal of Clinical Nutrition</u> , January 1998, pp. 2-4.					
J	CD	Griffen, MD, et al.; <i>Asymptomatic Mitral and Aortic Valve Disease Is Seen In Half of the Patients Taking 'Phen-Fen'</i> ; <u>ARCH INTERN MED</u> , Vol. 158, Jan. 12, 1998, pp. 102.					
J	CE	<i>Fluoxetine (Prozac) and Other Drugs For Treatment of Obesity</i> ; published in <u>The Medical Letter on Drugs and Therapeutics</u> ; Vol. 36 (Issue 936), November 25, 1994, pp. 107-108.					
J	CF	Len Griffen, MD, et al.; <i>The "Phen-Pro" Diet Drug Combination Is Not Associated With Valvular Heart Disease</i> ; <u>ARCH INTERN MED</u> , Vol. 158, June 8, 1998, pp. 1278-1279.					
J	CA	Riley et al.; <u>Drugs Facts and Comparisons</u> . 1999. Pages 239 (a), 264 (d), 264 (td).					
J	CB	Harvey, B.H.; Bouwer, C.D.; Department of Pharmacology, Potchefstroom University for Christian Higher Education, South Africa; <i>Neuropharmacology of paradoxical weight gain with selective serotonin reuptake inhibitors</i> ; Clin Neuropharmacol 2000 Mar-Apr; 23(2):90-7.					
J	CB	Fava, M., Depression Clinical and Research Program, Massachusetts General Hospital, Boston 02114, USA, <i>Weight gain and antidepressants</i> , J. Clin Psychiatry 2000;61 Suppl 11(1-2):37-41.					
EXAMINER <i>[Signature]</i>				DATE CONSIDERED <i>6/04</i>			
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							
REFERENCE DESIGNATION				U.S. PATENT AND PUBLISHED APPLICATION DOCUMENTS			



UNPUBLISHED US APPLICATIONS NOT RELATED BY PRIORITY (COPIES ENCLOSED)		ATTY DOCKET NO.: J02.4-1128-US01		APPLICATION NO. 10/715912		
		APPLICANT: Martin C. Hinz				
		FILING DATE: November 18, 2003		GROUP: 1616		
OTHER ART (Including Author, Title, Date, Pertinent Pages, Ect.)						
J	CA	Fava, M.; Judge, R.; Hoog, S. L.; Nilsson, M. E.; Koke, S. C.; Massachusetts General Hospital, Boston 02114, USA; <i>Fluoxetine versus sertraline and paroxetine in major depressive disorder: changes in weight with long-term treatment</i> ; J. Clin Psychiatry 2000 Nov; 61(11):863-7. [MEDLINE record in process]				
	CB	American College of Neuropsychopharmacology Annual Meeting in San Juan; SAN JUAN, Puerto Rico, Dec. 15, 2000; PR Newswire.				
	CC	Leinonen, E.; Skarstein, J.; Behnke, K.; Agren, H.; Helsdingen, J.T.; Department of Psychogeriatrics, Tampere University Hospital Pitkaniemi, Finland; <i>Efficacy and tolerability of mirtazapine versus citalopram: a double-blind, randomized study in patients with major depressive disorder. Nordic Antidepressant Study Group.</i> ; Int Clin Psychopharmacol, 1999 Nov; 14(6):329-37.				
	CD	Michael Anchors, M.D., PH.D., Professor of Medicine, Georgetown University Medical School; Anchors (US Patent 5,795,895) book; "Safer than Phen-fen"; page 82.				
	CE	Rochat, B.; Baumann, P.; Audus, K.L.; Department of Pharmaceutical Chemistry, University of Kansas, 2095 Constant Avenue, Lawrence, KS 66047, USA; <i>Transport mechanisms for the antidepressant citalopram in brain microvessel endothelium</i> ; Brain Res, 1999 Jun 12; 831(1-2):229-36.				
J	CF	Foglia, J. P.; Pollock, B.G.; Kirshner, M.A.; Rosen, J.; Sweet, R.; Mulsant, B.; Department of Psychiatry, University of Pittsburgh, School of Medicine, PA 15212, USA; <i>Plasma levels of citalopram enantiomers and metabolites in elderly patients</i> ; Psychopharmacol Bull, 1997; 33(1):109-12.				
UNPUBLISHED US APPLICATIONS NOT RELATED BY PRIORITY						
EXAM'S INIT.		APPLICATION NO.	FILING DATE	INVENTOR(S)		
	DA					
	DB					
US APPLICATIONS RELATED BY PRIORITY (COPIES NOT ENCLOSED)		ATTY DOCKET NO.: J02.4-1128-US01		APPLICATION NO. 10/715912		
		APPLICANT: Martin C. Hinz				
		FILING DATE: November 18, 2003		FILING DATE: November 18, 2003		
US APPLICATIONS RELATED BY PRIORITY						
EXAM'S INIT.		APPLICATION NO.	FILING DATE	PATENT NO.	INVENTOR(S)	FORM 1449/892 ENC
J	EA	09/412,701	10/05/1999	6403657	Hinz	
J	EB	09/942188	8/29/2001		Hinz	
	EC					
	ED					
EXAMINER				DATE CONSIDERED 6/04		
EXAMINER: Initial if application considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.						